Daily Stock Analysis, ICLR, ICON PLC, priceseries

ICON PLC. Daily Stock Analysis
Stock Information
Open
199.00
Close
198.07
High
199.17
Low
195.87
Previous Close
198.66
Daily Price Gain
-0.59
YTD High
223.62
YTD High Date
Jan 21, 2021
YTD Low
168.76
YTD Low Date
Mar 3, 2021
YTD Price Change
6.05
YTD Gain
3.15%
52 Week High
223.62
52 Week High Date
Jan 21, 2021
52 Week Low
145.11
52 Week Low Date
May 5, 2020
52 Week Price Change
47.19
52 Week Gain
31.28%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 21. 2017
105.30
Sep 13. 2017
112.66
16 Trading Days
6.99%
Link
LONG
May 30. 2018
125.90
Jun 25. 2018
133.76
18 Trading Days
6.24%
Link
LONG
Nov 13. 2019
150.30
Dec 4. 2019
158.25
14 Trading Days
5.29%
Link
LONG
Jul 13. 2020
171.79
Jul 24. 2020
183.28
9 Trading Days
6.69%
Link
LONG
Sep 25. 2020
183.14
Oct 15. 2020
205.51
14 Trading Days
12.21%
Link
LONG
Jan 5. 2021
195.69
Jan 26. 2021
210.65
14 Trading Days
7.65%
Link
Company Information
Stock Symbol
ICLR
Exchange
NasdaqGS
Company URL
http://www.iconplc.com
Company Phone
00 353 1 291 2000
CEO
Stephen A. Cutler
Headquarters
-
Business Address
SOUTH COUNTY BUSINESS PARK, LEOPARDSTOWN
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Laboratories & Research
CIK
0001060955
About

ICON Plc engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It provides Phase I-IV clinical trial management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Description

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. Its clinical development services comprise product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. The company's clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for US government agencies, electronic transmission of test results, and electronic patient reported outcomes. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.